Tonix's New Fibromyalgia Drug Gains FDA Approval Amid Strong Trials
TL;DR Summary
Tonix Pharmaceuticals received FDA approval for Tonmya™, a non-opioid, sublingual tablet for fibromyalgia in adults, marking the first new treatment in over 15 years. The drug demonstrated significant pain reduction in Phase 3 trials and is expected to launch in Q4 2025, targeting over 10 million affected U.S. adults.
- First New Fibromyalgia Drug in 15 Years: Tonix's Tonmya Approved for 10M+ US Patients After Strong Trial Results Stock Titan
- Anticipating TNX-102 SL's Addition to the Fibromyalgia Toolkit, with Andrew Sharobeem, DO HCPLive
- US FDA approves Tonix Pharma's drug to manage pain related to chronic condition Reuters
- Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights GlobeNewswire
- Tonix Pharmaceuticals stock halted ahead of FDA approval news Investing.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
19 min
vs 20 min read
Condensed
99%
3,865 → 49 words
Want the full story? Read the original article
Read on Stock Titan